首页> 美国卫生研究院文献>Journal of Medicine and Life >Construction of recombinant fusion protein of influenza a virus neuraminidase and heat shock protein 70 gene: expression in baculovirus and bioactivity
【2h】

Construction of recombinant fusion protein of influenza a virus neuraminidase and heat shock protein 70 gene: expression in baculovirus and bioactivity

机译:流感病毒神经氨酸酶和热休克蛋白70重组融合蛋白的构建基因:在杆状病毒中的表达和生物活性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Background: Two structural antigens, hemagglutinin and neuraminidase, are a major component for the development of influenza vaccine candidates. Recombinant vaccines are produced by a simple method, although expected to induce an immune response to a specific antigen, remaining to be further improved for their high effectiveness. In general, heat shock protein 70 of Mycobacterium tuberculosis, as a potent adjuvant, is commonly used to improve antigen-presenting cell (APC) function and thereby elicit T lymphocytes.>Objective: The purpose of this research was to evaluate the efficacy of the NA antigen fused to the C-terminus of HSP70, as a vaccine candidate, in the induction of potent, protective immune answers specific to the vaccine antigen.>Material and Method: The NA gene was strengthened via a polymerase chain reaction and then cloned to a eukaryotic expressing vector pFastBac HTA. Subsequently, a recombinant NA protein fusing to HSP70 was expressed in Baculovirus. The purity of the expressed NA-HSP70 fusion protein was investigated on the SDS-PAGE electrophoresis. Western blot was carried out to investigate the expression of NA-HSP70. Additionally, an immunofluorescence assay was used qualitatively to assess the biological and antigenicity activity profiles of the protein of recombinant, NA-HSP70, on the infected Sf9 cell surface by using immunized rabbit antiserum.>Result and conclusion: Interestingly, the findings in the present studies suggested that HSP proteins have the ability to both stimulate and increase potent humoral- and cell-mediated immune responses, and play an adjuvant role when combined with other proteins. Therefore, a recombinant protein fusing to HSP raised hope regarding the development of an HSP-based vaccine.
机译:>背景:两种结构抗原,血凝素和神经氨酸酶是开发流感疫苗候选物的主要成分。重组疫苗是通过简单的方法生产的,尽管有望诱导对特定抗原的免疫反应,但由于其高效性而有待进一步改进。通常,结核分枝杆菌的热休克蛋白70作为有效佐剂,通常用于改善抗原呈递细胞(APC)的功能,从而诱发T淋巴细胞。>目的:评估与HSP70 C末端融合的NA抗原(作为候选疫苗)在诱导针对疫苗抗原的有效保护性免疫应答中的功效。>材料和方法:该基因通过聚合酶链反应得到增强,然后克隆到真核表达载体pFastBac HTA中。随后,在杆状病毒中表达与HSP70融合的重组NA蛋白。在SDS-PAGE电泳上研究了表达的NA-HSP70融合蛋白的纯度。进行了蛋白质印迹以研究NA-HSP70的表达。此外,通过免疫兔抗血清,定性使用了免疫荧光法评估了重组蛋白NA-HSP70在被感染的Sf9细胞表面的生物学和抗原活性。>结果和结论:目前的研究结果表明,HSP蛋白具有刺激和增强体液和细胞介导的免疫应答的能力,并且在与其他蛋白结合时起辅助作用。因此,融合至HSP的重组蛋白引起了对基于HSP的疫苗的开发的希望。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号